{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","groups":[{"description":"Patients received six 21-day cycles of therapy, up to a maximum of 8 cycle. Each cycle comprised of denileukin diftitox plus CHOP (cyclophasphamide, doxorubicin, vincristine, prednisone)","id":"OG000","title":"Denileukin Diftitox/CHOP Administration"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"After 4 years","title":"Number of Patients That Achieved a Complete Response (CR)","type":"PRIMARY","unitOfMeasure":"participants"}